| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
61,456,000 |
| Market
Cap: |
861.00(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.9 - $16.15 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CareDx together with its subsidiaries, is a medicine company focused on the discovery, development and commercialization of diagnostic solutions for transplant patients and caregivers. Co. provides testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey, and is a provider of genomics-based information for transplant patients. Co.'s commercially available testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, AlloMap® Heart, a solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure® Lung.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
38,810 |
106,345 |
| Total Sell Value |
$0 |
$0 |
$359,527 |
$1,585,048 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
9 |
21 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Maag Peter |
See Remarks |
• • – |
2019-04-12 |
4 |
AS |
$29.11 |
$2,910,530 |
D/D |
(100,000) |
438,406 |
|
- |
|
| King Sasha |
Chief Commercial Officer |
• – – |
2019-04-12 |
4 |
AS |
$29.81 |
$298,064 |
D/D |
(10,000) |
76,594 |
|
- |
|
| King Sasha |
Chief Commercial Officer |
• – – |
2019-04-12 |
4 |
OE |
$1.00 |
$64,920 |
D/D |
12,707 |
86,594 |
|
- |
|
| Maag Peter |
See Remarks |
• • – |
2019-04-09 |
4 |
OE |
$2.30 |
$466,587 |
D/D |
80,000 |
538,406 |
|
- |
|
| Goldberg Michael |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
806 |
85,546 |
|
- |
|
| Bickerstaff George |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
514 |
86,967 |
|
- |
|
| Snyderman Ralph |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
343 |
61,184 |
|
- |
|
| Bickerstaff George |
Director |
– • – |
2019-03-21 |
4 |
OE |
$1.12 |
$36,938 |
D/D |
32,980 |
86,453 |
|
- |
|
| Goldberg Michael |
Director |
– • – |
2019-03-14 |
4 |
S |
$37.36 |
$1,867,825 |
D/D |
(50,000) |
84,740 |
|
- |
|
| Yee James P |
Chief Medical Officer |
• – – |
2019-03-12 |
4 |
AS |
$35.18 |
$267,282 |
D/D |
(7,598) |
43,409 |
|
- |
|
| Maag Peter |
See Remarks |
• • – |
2019-03-11 |
4 |
AS |
$34.23 |
$1,711,280 |
D/D |
(50,000) |
458,406 |
|
- |
|
| Maag Peter |
See Remarks |
• • – |
2019-03-01 |
4 |
D |
$31.64 |
$705,920 |
D/D |
(22,311) |
508,406 |
|
- |
|
| Maag Peter |
See Remarks |
• • – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
530,717 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-03-01 |
4 |
AS |
$31.36 |
$407,742 |
D/D |
(13,000) |
77,290 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-03-01 |
4 |
D |
$31.64 |
$372,403 |
D/D |
(11,770) |
90,290 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
102,060 |
|
- |
|
| Yee James P |
Chief Medical Officer |
• – – |
2019-03-01 |
4 |
D |
$31.64 |
$116,593 |
D/D |
(3,685) |
51,007 |
|
- |
|
| Yee James P |
Chief Medical Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
54,692 |
|
- |
|
| King Sasha |
Chief Commercial Officer |
• – – |
2019-02-22 |
4 |
AS |
$29.03 |
$217,725 |
D/D |
(7,500) |
73,887 |
|
- |
|
| King Sasha |
Chief Commercial Officer |
• – – |
2019-02-22 |
4 |
OE |
$5.90 |
$44,250 |
D/D |
7,500 |
81,387 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-02-20 |
4 |
AS |
$26.30 |
$57,860 |
D/D |
(2,200) |
77,060 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-02-20 |
4 |
OE |
$1.00 |
$8,204 |
D/D |
2,062 |
79,260 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-02-15 |
4 |
AS |
$25.40 |
$714,299 |
D/D |
(28,122) |
77,198 |
|
- |
|
| Bell Michael Brian |
Chief Financial Officer |
• – – |
2019-02-15 |
4 |
OE |
$1.00 |
$125,205 |
D/D |
28,122 |
105,320 |
|
- |
|
| King Sasha |
Chief Commercial Officer |
• – – |
2019-02-15 |
4 |
AS |
$25.00 |
$62,500 |
D/D |
(2,500) |
73,887 |
|
- |
|
800 Records found
|
|
Page 20 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.60 (4.11%) 
